Microdosing Tirzepatide or Semaglutide: What the Evidence Says and Which Providers Offer It

Microdosing means taking tirzepatide or semaglutide below the doses on the drug's label, usually to ease side effects or lower the cost. No randomized trial has tested it as a weight-loss strategy, and a 2026 expert commentary describes high-quality evidence as essentially absent¹. Many telehealth programs sell microdose plans anyway, so check the dose and price you'd get.

That doesn't make microdosing dangerous by default, and it doesn't make it useless. It means the claims around it run ahead of the data. This guide sets out what counts as a microdose, what the trials can and can't tell you, which telehealth programs sell it, and what to ask before you pay.

What counts as a microdose?

There's no official definition. A 2026 commentary in Expert Opinion on Pharmacotherapy describes microdosing as typically using 25% to 50% of the manufacturer's recommended starting dose, or stretching the time between doses¹. It notes the practice spread during the drug shortages through patient communities, telemedicine weight-loss programs and clinician anecdote, including "click counting" on multidose pens to measure out partial doses¹. The same commentary flags the safety questions that come with it: compounded products, nonstandard ways of measuring a dose, and whether the dose a person takes is the dose they meant to take¹. Pens are designed and labeled to deliver set doses, so a partial dose is something the pen's instructions don't cover.

The reference point is the label. Each approved drug has a starting dose, used only to build tolerance, and maintenance doses that the trials tested for weight loss:

The Zepbound label is explicit that the 2.5 mg dose is for starting treatment and is not approved as a maintenance dose². The Wegovy label treats 0.25 mg the same way: a starting dose, followed by an increase every four weeks³.

A microdose sits below the starting dose, or between the starting dose and the lowest maintenance dose, held there indefinitely. Programs describe their own versions very differently. Among the plans we track, one describes ranges as low as 0.05 mg of semaglutide, another sells a single 1 mg tirzepatide program and nothing else, and a third publishes no milligram figure at all.

What do the trials say about low doses?

Only indirectly. The pivotal trials tested the labeled maintenance doses, not microdoses. The lowest doses they did test show that weight loss depends on dose:

Two things follow. First, a lower dose still works: tirzepatide's lowest maintenance dose produced 15% average weight loss⁴. Second, results fell as doses fell, and nothing in these trials tells you what happens below the lowest dose tested. On the labels, the 2.5 mg tirzepatide and 0.25 mg semaglutide starting doses last four weeks before the first increase, so they weren't tested as long-term doses either^2,3.

The 2026 commentary reports that early accounts suggest less nausea, better adherence and modest weight loss, but stresses that high-quality evidence remains limited and that concerns about compounded products and dose accuracy persist¹.

Who might it suit, and who not?

That's a decision for you and your prescriber, and the label already gives prescribers room before anyone goes off-label. The Wegovy label allows a dose increase to be delayed by four weeks if a step isn't tolerated, and lists 1.7 mg as an alternative maintenance dose to 2.4 mg³. The Zepbound label says that if a maintenance dose isn't tolerated, a lower maintenance dose can be considered².

People usually ask about microdosing for one of four reasons: side effects at standard doses, cost, staying on a GLP-1 after reaching a goal weight, or general health goals that programs often market as "longevity." The first three have labeled options worth raising with a prescriber first. The last one has the least evidence behind it.

If your aim is substantial weight loss, the trial data points the other way: the higher maintenance doses produced the larger average results⁴.

Which providers offer microdose plans, and what do they cost?

Of the 591 telehealth programs we track, 85 sell a microdose or low-dose GLP-1 line, typically as compounded medication. The FDA notes that compounded drugs are not FDA-approved, which means it does not check their safety, effectiveness or quality before they're sold⁸. Here are four with a published price:

yourEra (Partner) also sells microdosing protocols alongside standard compounded semaglutide and tirzepatide. Prices change, so confirm the figure at checkout.

For context, a standard-dose plan isn't always much more. Across the telehealth programs in our price index, the median month-to-month price is $199 for compounded semaglutide and $273 for compounded tirzepatide, and a quarter of programs charge $159 or less for semaglutide. Some of them charge one price at every dose. If cost is your main reason for a microdose, compare it with a full-dose plan at the low end of that range before deciding that less drug is the cheaper route.

The wider market varies a lot. Among the programs we track, one charges the same for its microdose line as for its full dose at every term, so you'd pay the same for less drug. Another headlines a microdose price that is a promotional rate below its list price. A third headlines a microdose page with a promise of zero side effects. If a plan's price or promises look unusual, read its review before you pay.

What to ask before signing up

Get answers to these in writing before you prepay:

• What dose, in milligrams? Not "units" or "clicks." If you're drawing from a vial, the units depend on its concentration; our units-to-mg guide explains the conversion.
• Is it compounded or brand-name? If compounded, which pharmacy makes it? The FDA has received reports of adverse events, some needing hospital care, that may be related to people measuring the wrong dose of compounded semaglutide, and others possibly related to doses beyond the label⁷.
• How long will one vial last? The FDA recommends throwing away a multidose vial 28 days after first use, even if medication is left, because the contamination risk rises after that⁷. A small dose from a large vial means discarding drug, or being told to break that rule.
• What does it cost per month, and for how long? Check whether the price needs a prepaid term, and whether it's lower than the program's full-dose price.
• Can you move to a labeled dose on the same plan? If the microdose isn't enough, you shouldn't have to switch programs to step up.

What to do next

If side effects at a standard dose are the problem, start with your prescriber and the label's own options: a slower step-up or a lower maintenance dose^2,3. Our tirzepatide dosage chart shows the labeled schedule.

If you've decided on a microdose plan, compare prices on the tirzepatide board or the semaglutide board, where month-to-month prices are listed side by side. If you plan to stay on treatment for the long run, our guide to the best GLP-1 provider for long-term use covers what matters after the first few months. The 2-minute quiz asks about budget, format and goals, then matches you with programs that fit.